CLChad A. LaGrange

Chad A. LaGrange

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Chad A. LaGrange has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Carcinosarcoma of the Tunica Vaginalis Following Radiation Therapy for Localized Prostate Cancer.

    by Charles D. Viers, Subodh M. Lele, Tara Kirkpatrick, Chad A. LaGrange


  • Open Access

    Lymphoepithelioma-like, a variant of urothelial carcinoma of the urinary bladder: a case report and systematic review for optimal treatment modality for disease-free survival

    by Andy W. Yang, Aydin Pooli, Subodh M. Lele, Ina W. Kim, Judson D. Davies, Chad A. LaGrange

    Lymphoepithelioma-like carcinoma (LELC) is a rare high-grade carcinoma that resembles nasopharyngeal lymphoepithelioma and can occur throughout the body. First reported in 1991, bladder LELC has an incidence of about 1% of all bladder carcinomas. Due to its rare occurrence, prognoses and ideal treatment guidelines have not been clearly defined. A PubMed search was performed using two terms, “lymphoepithelioma-like carcinoma” and “bladder.” Review articles, articles in foreign languages, expression studies, and studies not performed in the bladder were excluded. We report a case of LELC of the bladder including treatment and outcome and performed a systematic review of all 36 available English literatures from 1991 to 2016 including the present case to identify factors affecting disease-free survival. One hundred forty cases of bladder LELC were analyzed. The mean age of the patients was 70.1 years ranging from 43 to 90 years with 72% males and 28% females. Pure LELC occurs most often at 46% followed by mixed LELC 28% and predominant LELC 26%. EBV testing was negative in all cases tested. Mean follow-up length for all cases was 33.8 months with no evidence of disease in 62.2%, while 11.1% died of disease, 10.4% alive with metastasis, and 8.2% died without disease. 5.0% of cases had recurrence at an average of 31.3 months. Prognosis is significantly favorable for patients presenting with pure or predominant forms of LELC compared to mixed type (p < 0.0001). The treatment significantly associated with the highest disease mortality and lowest disease-free survival was TURBT alone when compared to any multi-modality treatment (p < 0.01). We conclude that the best treatment modality associated with the highest disease-free survival is multi-modal treatment including radical cystectomy.


  • Open Access

    Human Prostatic Acid Phosphatase: Structure, Function and Regulation

    by Sakthivel Muniyan, Nagendra K. Chaturvedi, Jennifer G. Dwyer, Chad A. LaGrange, William G. Chaney, Ming-Fong Lin

    Human prostatic acid phosphatase (PAcP) is a 100 kDa glycoprotein composed of two subunits. Recent advances demonstrate that cellular PAcP (cPAcP) functions as a protein tyrosine phosphatase by dephosphorylating ErbB-2/Neu/HER-2 at the phosphotyrosine residues in prostate cancer (PCa) cells, which results in reduced tumorigenicity. Further, the interaction of cPAcP and ErbB-2 regulates androgen sensitivity of PCa cells. Knockdown of cPAcP expression allows androgen-sensitive PCa cells to develop the castration-resistant phenotype, where cells proliferate under an androgen-reduced condition. Thus, cPAcP has a significant influence on PCa cell growth. Interestingly, promoter analysis suggests that PAcP expression can be regulated by NF-κB, via a novel binding sequence in an androgen-independent manner. Further understanding of PAcP function and regulation of expression will have a significant impact on understanding PCa progression and therapy.


  • Effect of Robotic Manipulation on Unidirectional Barbed Suture Integrity: Evaluation of Tensile Strength and Sliding Force

    by Dharam Kaushik, Kevin Clay, S.G.M Hossain, Eugene Park, Carl A. Nelson, Chad A. LaGrange

    Background and Purpose: One of the more challenging portions of robot-assisted radical prostatectomy (RARP) is the urethrovesical anastomosis. Because of this, a unidirectional absorbable barbed suture (V-Loc™) has been used to complete the anastomosis with better efficiency and less tension. The effect of robotic needle driver manipulation on barbed suture is unknown. Therefore, the aim of this study is to determine whether robotic manipulation decreases the tensile strength and peak sliding force of V-Loc barbed suture. Materials and Methods: Fifty-six V-Loc sutures were compared with 56 Maxon sutures. All sutures were 3-0 caliber. Half of the sutures in each group were manipulated with a da Vinci® robot large needle driver five times over a 5 cm length of suture. The other half was not manipulated. Breaking force was determined by placing sutures in a Bose ElectroForce load testing device. For sliding force testing, 28 V-Loc sutures were manipulated in the same fashion and compared with 28 nonmanipulated V-Loc sutures. Peak force needed to make the suture slip backward in porcine small intestine was determined to be the sliding force. Scanning electron microscopy of the barbs before and after robotic manipulation was also performed. Results: The mean difference in breaking forces for manipulated vs nonmanipulated Maxon sutures was 4.52 N (P=0.004). The mean difference in breaking forces for manipulated vs nonmanipulated V-Loc sutures was 1.30 N (P=0.046). The manipulated V-Loc group demonstrated a lower peak sliding force compared with the nonmanipulated group (0.76 vs 0.88 N, P=0.199). Electron microscopy revealed minor structural damage to the barbs and suture. Conclusion: Tensile strength and peak sliding force of V-Loc suture is decreased by robotic manipulation. This is likely because of structural damage to the suture and barbs. This structural damage, however, is likely not clinically significant.


  • The Effect of Sodium Thiosulfate Administration on Nephrocalcinosis in a Rat Model

    by Chad A. LaGrange, Subodh M. Lele, Vernon M. Pais

    Introduction: Sodium thiosulfate (STS) is a U.S. Food and Drug Administration (FDA)–approved chelating agent that is used for the treatment of cyanide poisoning and prophylaxis against cisplatin nephropathy. Recently, STS has also been used in the treatment of calciphylaxis, which is a disease characterized by calcification in the soft tissues with vascular calcification and thrombosis causing nonhealing ulcers. We proposed a rat model to evaluate whether STS has any possible beneficial effect on calcium nephrolithiasis or nephrocalcinosis. Methods: Twenty-one male Sprague-Dawley rats were used in the study. All animals received standard rat chow throughout the experiment. The animals were started on special drinking water containing 0.4% ethylene glycol plus 1.0% ammonium chloride for 7 days to induce crystalluria and nephrocalcinosis. The animals were then randomized to two groups. Group 1 served as a control and received daily intraperitoneal injections of normal saline. Group 2 received daily intraperitoneal injections of STS solution. Special drinking water containing 0.8% ethylene glycol was continued during the treatment period. Results: Group 2 gained significantly less weight than group 1 (18.0% v 8.5%, p < 0.05). The amount of crystalluria in group 2 was much less than that in group 1, but did not reach statistical significance (0.7 v 4.2, p = 0.09). Degree of calcification noted in the kidneys was not statistically different between the two groups. Conclusions: The current study did not reveal any significant benefit of STS administration on calcium stone disease. However, many more studies are necessary before the possibility of a beneficial effect is completely disproved.